摘要
目的 探讨原发性阴道癌临床预后及治疗方法。方法 16例原发性阴道癌采用放疗加顺铂、5 -FU及丝裂霉素三联全身化疗 ,单行放疗者 2 8例。结果 5年及 10年存活率为 5 0 9%和 38 1%。Ⅱ期 3年及 5年存活率为 74 5 %和 6 1 1% ,Ⅲ期 3年及 5年存活率为 5 6 8%和 45 1% ,Ⅳ期 3年及 5年存活率为 0 ,Ⅱ期与Ⅲ期3年及 5年存活率比较P <0 0 5。鳞癌 3年及 5年存活率显著高于腺癌 (P <0 0 1)。放射治疗总剂量 <6 0Gy组的局部复发率显著高于放射治疗总剂量≥ 6 0Gy组 (P <0 0 5 )。肿瘤位于阴道上段及中段者 5年存活率明显高于阴道下段及全段者 (分别为P <0 0 1、P <0 0 5 )。放化疗的完全缓解率及 5年存活率均显著高于单行放疗者(P <0 0 5 )。结论 原发性阴道癌的预后与期别、病理类型、癌肿的生长部位、治疗方法及放射剂量有关。
Objective\ To discuss the prognostic factors of primary carcinoma in vagina and treatment methods.Method\ 16 patients were treated by combination of radiotherapy and chemotherapy,using such agents as 5-FU,mitomycin and cisplatin.28 cases were treated by radiotherapy alone.Result\ 5-year survival rate and 10-year survival rate were 50.9% and 38.1% respectively.3-year and 5-year survival rates in stage Ⅱ were 74.5% and 61.1% respectively.3-year and 5-year survival rates in stage Ⅲ were 56.8% and 45.1% respectively.3-year and 5-year survival rates in stage Ⅳ were 0.There was a significant difference in 3-year and 5-year survival rate of FIGO stage Ⅱ,compared with FIGO stage Ⅲ(P<0.05).Patients with squamous cell carcinoma had a significantly greater 3-year and 5-year survival rate compared with that in patients with adenocarcinoma(P<0.01).Radiotherapy with a total dose of less than 60Gy had a significantly greater local recurrent rate compared with that with more than 60Gy (P<0.05).Patients with involvement of lower one-third or the total of the canal had a significant lower 5-year survival rate than those with involvement of upper two-thirds of the canal(P<0.01).The patients with combination therapy had higher complete response and 5-year survival rate compared with patients treated by radiotherapy alone(P<0.05).Conclusion\ The prognostic factors include stage,pathology,tumor position,treatment method and radiotherapy dose.
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2000年第2期96-98,共3页
Chinese Journal of Practical Gynecology and Obstetrics
关键词
原发性
阴道癌
鳞癌
腺癌
治疗
预后
Primary carcinoma of vagina\ Squamous cell carcinoma\ Adenocarcinoma\ Chemotherapy\ Radiotherapy
